Warner Chilcott PLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Warner Chilcott PLC
In this edition of the Coronavirus Notebook, an EU consortium uses a supercomputing platform to identify the generic drug raloxifene as a potential COVID-19 treatment, and the World Health Organization proposes a set of principles for distributing a coronavirus vaccine at global level.
Lantern, Avidity, Generation Bio and Vaxcyte launched initial public offerings during the second week of June as biopharma continues to intrigue IPO investors. Also, Blackstone invested $350m in Reata's bardoxolone and Checkmate’s $85m series C led recent VC deals.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.
- Other Names / Subsidiaries
- Galen Holdings PLC